Health Care [ 11/12 ] | Biotechnology [ 66/75 ]
NASDAQ | Common Stock
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States.
Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors.
In addition, it is developing bispecific antibodies, which are in preclinical stage.
It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute.
The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005.
TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 24 | -0.94 Decreased by -527.27% | -1.05 Increased by +10.48% |
| May 14, 24 | -1.33 Decreased by -269.44% | -1.19 Decreased by -11.76% |
| Mar 5, 24 | 0.01 Increased by +103.23% | -0.08 Increased by +112.50% |
| Nov 9, 23 | 0.29 Increased by +196.67% | -0.06 Increased by +583.33% |
| Aug 14, 23 | 0.22 Increased by +170.97% | -0.10 Increased by +320.00% |
| May 10, 23 | -0.36 Increased by +25.00% | -0.26 Decreased by -38.46% |
| Mar 8, 23 | -0.31 Increased by +22.50% | -0.27 Decreased by -14.81% |
| Nov 14, 22 | -0.30 Increased by +21.05% | -0.28 Decreased by -7.14% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 55.00 K Decreased by -99.39% | -2.84 M Increased by +54.84% | Decreased by -5.16 K% Decreased by -7.29 K% |
| Mar 31, 24 | 100.00 K Increased by +N/A% | -3.17 M Increased by +70.89% | Decreased by -3.17 K% Decreased by N/A% |
| Dec 31, 23 | 3.04 M Increased by +N/A% | 439.00 K Increased by +106.07% | Increased by +14.42% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | 10.76 M Increased by +265.76% | Increased by +N/A% Decreased by N/A% |
| Jun 30, 23 | 9.00 M Increased by +N/A% | -6.29 M Decreased by -1.17% | Decreased by -69.84% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -10.88 M Decreased by -14.88% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Increased by +100.00% | -7.23 M Increased by +6.21% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -6.49 M Increased by +6.60% | Decreased by N/A% Decreased by N/A% |